Needham, Absci

Absci shares jump as analyst lauds 'practical' AI drug company
"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...
Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside
Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...
Absci Looks Cheap And Positioned For Growth With AMD's AI Backing
Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I ...
H.C. Wainwright Reaffirms Their Buy Rating on AbSci (ABSI)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.
AMD invests $20M in AI-powered drug discovery company Absci
Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop new hardware and software optimized for the healthcare sector. The effort ...
Absci, Owkin announce partnership to bring together AI platforms
Absci (ABSI) and Owkin announced a partnership bringing together two leading AI platforms to rapidly discover and design ...
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the company entered into a strategic collaboration with Advanced Micro Devices Inc ...
Top 10 Medical AI Stocks on Wall Street’s Radar
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...